Intercalates into DNA and inhibits topoisomerase II.

Adjuvant therapy for breast cancer (node-positive after resection).

Treatment of multiple cancers including:

• • Acute lymphoblastic leukemia (ALL)

  • Acute myeloblastic leukemia (AML)

  • Hodgkin and non-Hodgkin lymphoma

  • Metastatic cancers: breast, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, ovarian, bladder, thyroid, gastric, and bronchogenic carcinoma.

Single agent: 60–75 mg/m² IV every 21 days

In combination: 40–75 mg/m² IV every 21–28 days

Breast cancer (adjuvant): 60 mg/m² IV on day 1 every 21 days for 4 cycles with cyclophosphamide

Alopecia (92% incidence in AC regimen)

Nausea/Vomiting

Myelosuppression (leukopenia, thrombocytopenia)

Severe cardiac conditions or recent myocardial infarction

Persistent myelosuppression

Severe hepatic impairment (bilirubin > 5 mg/dL)

Hypersensitivity to doxorubicin

Cardiomyopathy and Arrhythmias

Secondary Malignancies

Extravasation and Tissue Necrosis

Severe Myelosuppression

Use in Patients with Hepatic Impairment

Tumor Lysis Syndrome

Radiation Sensitization and Radiation Recall

Embryofetal Toxicity